down arrow

Champions Oncology, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US15870P3073
USD
6.10
0.04 (0.73%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.986.10

52 Week

4.1611.99
Valuation
Technical
Day's Volume

CASH

1.31 k

Shareholding (Jan 2025)

FII

0.23%

Held by 6 FIIs

DII

66.79%

Held by 4 DIIs

Promoter

29.92%

What does Champions Oncology, Inc. do?

22-Jun-2025

Champions Oncology, Inc. develops and sells technology solutions to personalize oncology drug development, with recent net sales of $17 million and a market cap of $111.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap.

Overview: <BR>Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 17 Million (Quarterly Results - Jan 2025) <BR>Most recent Net Profit: 4 Million (Quarterly Results - Jan 2025) <BR>Market-cap: USD 111.31 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.30 <BR>Return on Equity: 117.52% <BR>Price to Book: 20.35<BR><BR>Contact Details: <BR>Address: 855 N Wolfe St Ste 619, BALTIMORE MD: 21205-1511 <BR>Tel: 1 410 3690365 <BR>Website: https://championsoncology.com

Read More

Who are in the management team of Champions Oncology, Inc.?

22-Jun-2025

As of March 2022, the management team of Champions Oncology, Inc. includes Chairman Joel Ackerman, CEO Dr. Ronnie Morris, Lead Independent Director Dr. David Sidransky, and several Independent Directors: Dr. Philip Breitfeld, Mr. Daniel Mendelson, Mr. Abba Poliakoff, and Mr. Scott Tobin. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Champions Oncology, Inc. includes the following members:<BR><BR>- Mr. Joel Ackerman, Chairman of the Board<BR>- Dr. Ronnie Morris, Chief Executive Officer and Director<BR>- Dr. David Sidransky, Lead Independent Director<BR>- Dr. Philip Breitfeld, Independent Director<BR>- Mr. Daniel Mendelson, Independent Director<BR>- Mr. Abba Poliakoff, Independent Director<BR>- Mr. Scott Tobin, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Champions Oncology, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data to assess Champions Oncology, Inc.'s current stance.

As of 1 October 2023, the technical data for Champions Oncology, Inc. is insufficient to form a view on its current stance.

Read More

Is Champions Oncology, Inc. overvalued or undervalued?

25-Jun-2025

As of November 1, 2023, Champions Oncology, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and other elevated valuation metrics compared to peers like Exact Sciences and Guardant Health, suggesting the market may be overestimating its growth potential.

As of 1 November 2023, Champions Oncology, Inc. moved from fair to overvalued. The company currently shows a price-to-earnings ratio of 45.2, a price-to-sales ratio of 10.5, and a price-to-book ratio of 7.8, which are significantly higher than its peers. In comparison, its competitor, Exact Sciences Corporation, has a price-to-earnings ratio of 32.1, while Guardant Health, Inc. stands at 25.4, indicating that Champions is trading at a premium relative to these companies.<BR><BR>Given the elevated valuation metrics and the recent performance of Champions' stock compared to the Sensex, which has shown stronger returns, it suggests that the market may be overestimating the growth potential of Champions Oncology. Therefore, the company is considered overvalued at this time.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Positive results for the last 4 consecutive quarters

  • OPERATING CASH FLOW(Y) Highest at USD 7.39 MM
  • NET PROFIT(HY) Higher at USD 2.66 MM
  • ROCE(HY) Highest at 503.05%
2

With ROE of 117.52%, it has a attractive valuation with a 17.42 Price to Book Value

3

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 94 Million (Micro Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.17

stock-summary
Return on Equity

124.63%

stock-summary
Price to Book

24.84

Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Apr 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.23%
0%
-12.23%
6 Months
-5.13%
0%
-5.13%
1 Year
41.2%
0%
41.2%
2 Years
15.09%
0%
15.09%
3 Years
-12.23%
0%
-12.23%
4 Years
-25.06%
0%
-25.06%
5 Years
-42.88%
0%
-42.88%

Champions Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.13%
EBIT Growth (5y)
39.59%
EBIT to Interest (avg)
-1.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
5.60
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.87%
ROCE (avg)
40.85%
ROE (avg)
24.39%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
17.42
EV to EBIT
13.93
EV to EBITDA
10.75
EV to Capital Employed
24.29
EV to Sales
1.60
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
174.42%
ROE (Latest)
117.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jan 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (3.06%)

Foreign Institutions

Held by 6 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -27.06% vs 25.93% in Jan 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -140.00% vs 542.86% in Jan 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.40",
          "val2": "17.00",
          "chgp": "-27.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "4.90",
          "chgp": "-126.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "4.50",
          "chgp": "-140.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-138.70%",
          "val2": "264.00%",
          "chgp": "-40.27%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 13.35% vs -6.86% in Apr 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 164.38% vs -37.74% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56.90",
          "val2": "50.20",
          "chgp": "13.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.50",
          "val2": "-5.10",
          "chgp": "227.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.70",
          "val2": "-7.30",
          "chgp": "164.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "85.10%",
          "val2": "-138.00%",
          "chgp": "22.31%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQstock-summary
Apr'25
Jan'25
Change(%)
Net Sales
12.40
17.00
-27.06%
Operating Profit (PBDIT) excl Other Income
-1.30
4.90
-126.53%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.80
4.50
-140.00%
Operating Profit Margin (Excl OI)
-138.70%
264.00%
-40.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Apr 2025 is -27.06% vs 25.93% in Jan 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is -140.00% vs 542.86% in Jan 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Apr'25stock-summary
Apr'25
Apr'24
Change(%)
Net Sales
56.90
50.20
13.35%
Operating Profit (PBDIT) excl Other Income
6.50
-5.10
227.45%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.70
-7.30
164.38%
Operating Profit Margin (Excl OI)
85.10%
-138.00%
22.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2025 is 13.35% vs -6.86% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 164.38% vs -37.74% in Apr 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Champions Oncology, Inc. stock-summary
stock-summary
Champions Oncology, Inc.
Pharmaceuticals & Biotechnology
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.
Company Coordinates stock-summary
Company Details
855 N Wolfe St Ste 619 , BALTIMORE MD : 21205-1511
stock-summary
Tel: 1 410 3690365
stock-summary
https://championsoncology.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."